We are live on ! Find out more
SM

SG3 Management Portfolio holdings

AUM $6.45K
1-Year Est. Return 61.81%
This Fund
S&P 500
This Quarter Est. Return
+12.91%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$1.62B
Cap. Flow
+$1.41B
Cap. Flow %
28.67%
Top 10 Hldgs %
36.75%
Holding
1,419
New
468
Increased
176
Reduced
163
Closed
410

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$208M
2
AMZN icon
Amazon
AMZN
+$165M
3
AMD icon
Advanced Micro Devices
AMD
+$86.9M
4
XYZ
Block Inc
XYZ
+$33.2M
5
ROKU icon
Roku
ROKU
+$27M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$10.3M
2
MRNA icon
Moderna
MRNA
+$9.79M
3
JD icon
JD.com
JD
+$6.14M
4
AZN icon
AstraZeneca
AZN
+$5.27M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.32M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 8.5%
2 Technology 4.33%
3 Communication Services 2.49%
4 Healthcare 1.87%
5 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1026
DELISTED
Apellis Pharmaceuticals
APLS
– –
-100,000
Closed -$3.3M
APLS
1027
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-291,100
Closed -$9.6M
APO icon
1028
Apollo Global Management
APO
$69B
– –
-30,500
Closed -$2.2M
ARKG icon
1029
CALL
ARK Genomic Revolution ETF
ARKG
$1.53B
– –
-22,000
Closed -$1.64M
ARKG icon
1030
PUT
ARK Genomic Revolution ETF
ARKG
$1.53B
– –
-33,000
Closed -$2.47M
ARWR icon
1031
Arrowhead Research
ARWR
$12.1B
– –
-14,849
Closed -$1.02M
ARWR icon
1032
PUT
Arrowhead Research
ARWR
$12.1B
– –
-30,000
Closed -$1.87M
ASAN icon
1033
CALL
Asana
ASAN
$1.96B
– –
-19,000
Closed -$1.97M
ASND icon
1034
Ascendis Pharma A/S
ASND
$16.5B
– –
-500
Closed -$80K
ASND icon
1035
PUT
Ascendis Pharma A/S
ASND
$16.5B
– –
-10,000
Closed -$1.59M
OPTU
1036
CALL
Optimum Communications Inc
OPTU
$298M
– –
-13,500
Closed -$280K
AVIR icon
1037
Atea Pharmaceuticals
AVIR
$370M
– –
-3,000
Closed -$46.8K
AVPT icon
1038
CALL
AvePoint
AVPT
$2.76B
– –
-183,400
Closed -$1.56M
AXSM icon
1039
CALL
Axsome Therapeutics
AXSM
$11.7B
– –
-10,000
Closed -$330K
AXSM icon
1040
PUT
Axsome Therapeutics
AXSM
$11.7B
– –
-4,200
Closed -$138K
BAX icon
1041
PUT
Baxter International
BAX
$12.8B
– –
-10,000
Closed -$804K
BBWI icon
1042
Bath & Body Works
BBWI
$3.97B
– –
-7,260
Closed -$458K
BDX icon
1043
CALL
Becton Dickinson
BDX
$46.4B
– –
-5,125
Closed -$1.23M
BGS icon
1044
CALL
B&G Foods
BGS
$303M
– –
-30,000
Closed -$897K
BKR icon
1045
CALL
Baker Hughes
BKR
$58.3B
– –
-6,500
Closed -$161K
BLK icon
1046
CALL
Blackrock
BLK
$167B
– –
-5,000
Closed -$4.19M
BLMN icon
1047
PUT
Bloomin' Brands
BLMN
$754M
– –
-478,000
Closed -$11.9M
BMY icon
1048
PUT
Bristol-Myers Squibb
BMY
$129B
– –
-13,300
Closed -$787K
BOX icon
1049
CALL
Box
BOX
$4.49B
– –
-25,000
Closed -$592K
BPMC
1050
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-60,100
Closed -$6.18M
40 41
42
43 44

Similar funds

EAM
Emso Asset Management London, United Kingdom $255K AUM 6.95% 1-Year Est. Return
CAM
Chatham Asset Management Chatham, New Jersey $376K AUM
CCM
Compton Capital Management Providence, Rhode Island $4.32M AUM 27.38% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
MAM
Moelis Asset Management New York $5.32M AUM
BGCI
Bertram Growth Capital III Foster City, California $6.05M AUM 39.41% 1-Year Est. Return
TPL
Tao Pro LLC San Francisco, California $13.8M AUM 74.14% 1-Year Est. Return
RC
Resonate Capital San Francisco, California $15.4M AUM 24.26% 1-Year Est. Return

SG3 Management's Q4 2021 Portfolio in Review

As of Q4 2021, SG3 Management held 1,419 positions worth $4.92B, up 49% from $3.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

SG3 Management deployed $1.41B of net new capital in Q4 2021, opening 468 new positions and adding to 176 existing holdings. Its largest new stake was Tesla: 619,500 shares worth $218M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 8.5% of assets, up from 0.74% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Moderna, an estimated $9.79M trimmed.

  • SG3 Management's largest Q4 2021 buy was Tesla: 619,500 shares worth $218M.
  • SG3 Management added most to Amazon in Q4 2021, an estimated $165M increase.
  • SG3 Management's biggest Q4 2021 reduction was Moderna, cutting an estimated $9.79M.
  • SG3 Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $10.3M.
  • SG3 Management's ten largest holdings make up 37% of its $4.92B portfolio in Q4 2021.
  • SG3 Management opened 468 new positions and closed 410 in Q4 2021.
  • SG3 Management's portfolio value rose 49% quarter-over-quarter to $4.92B.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.